Presentations
Freijer J., Greef I.d., Post T. and Ploeger B., Robust fitting of pharmacokinetic models to Phase II/III clinical trial data. PAGE.(2005). [Link to publication]
Winter W.d., Jongh J.d., Urquhart R., Moules I., Eckland D. and Danhof M., Mechanistic Disease Progression Analysis Indicates that Pioglitazone Improves ß-cell Function in Treatment-naïve Type 2 Diabetics. ADA.(2005).
Post T., Winter W.d., Jongh J.d., Urquhart R., Moules I., Eckland D. and Danhof M., Treatment efficacy of Pioglitazone in Combination Therapy on Disease Progression in Type 2 Diabetes Mellitus over a two-year period. ADA.(2005).
Winter W.d., Cascading Disease Progression Analysis in Type 2 Diabetes: Integrating multiple biomarkers into single mechanism-based model. PharmSciFair.(2005).
Post T.M., Winter W.d., Jongh J.d., Moules I., Urquhart R., Eckland D. and Danhof M., Treatment Efficacy of Combination-Therapy based on a Mechanistic Characterisation of Disease Processes in Type 2 Diabetes Mellitus over a two-year period. Figon.(2005).
Winter W.d., Post T., Jongh J.d., Urquhardt R., Moules I., Eckland D. and Danhof M.A., Mechanistic Disease Progression Model for Type 2 Diabetes Mellitus and Pioglitazone Treatment Effects. PAGE.(2004). [Link to publication]
Ploeger B., Houwing N., Bom A., Zollinger D. and Danhof M., Reversal of rocuronium-induced neuromuscular block by cyclodextin ORG 25969: model development and validation. PAGE.(2004). [Link to publication]
Ruigt G.S., Ploeger B., Danhof M., Bom A., Houwing N. and Iersel M.P.v., Development of a mechanism-based PK-PD model of the reversal of rocuronium-induced neuromuscular block by ORG25969. IARS.(2004). [Link to publication]
Winter W.d., Post T.M., Jongh J.d., Moules I., Urquhart R., Eckland D. and Danhof M., Disease Progression Analysis for Type 2 Diabetes Mellitus: Bridging Therapeutic Intervention and Disease Outcome. Figon.(2004).
Winter W.d., Jongh J.d., Eckland D. and Danhof M., Towards a Mechanistic Disease Progression Model for Type 2 Diabetes Mellitus. ASCPT.(2004).